Psoriasis  >>  Ozespa (briakinumab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ozespa (briakinumab) / AbbVie
NCT00292396: Efficacy and Safety of ABT-874 in Subjects With Moderate to Severe Chronic Plaque Psoriasis

Completed
2
180
US, Canada
Anti IL-12 monoclonal antibody/ABT-874, placebo
AbbVie (prior sponsor, Abbott)
Psoriasis
04/08
04/08

Download Options